insulin detemir + metformin

**insulin detemir + metformin** is a combination therapy consisting of two distinct drugs used in the management of type 2 diabetes mellitus. **Insulin detemir** is a long-acting recombinant human insulin analogue that provides sustained basal insulin coverage by binding to insulin receptors, enabling glucose uptake in tissues and suppressing hepatic glucose production. **Metformin** is a biguanide oral antihyperglycemic agent that primarily decreases hepatic glucose production (gluconeogenesis), increases peripheral glucose uptake and utilization, and improves insulin sensitivity. The combination targets both fasting and postprandial glucose control; metformin addresses insulin resistance and hepatic glucose output, while insulin detemir supplements deficient endogenous insulin. The combination is indicated for patients with type 2 diabetes who are inadequately controlled on oral agents alone[6][1][7].